{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:17:16Z","timestamp":1756898236986,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970188"],"award-info":[{"award-number":["81970188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-261"],"award-info":[{"award-number":["2022-PUMCH-A-261"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>\nThis is a retrospective, single-center PSM study evaluating the efficacy and safety of chidamide combined with the CHOEP (C-CHOEP) regimen versus the single CHOEP regimen in patients with untreated peripheral T cell lymphomas (PTCL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients<\/jats:title>\n                <jats:p>Patients newly diagnosed with PTCL between January 2015 and June 2021 were recruited, and were 1:1 divided into C-CHOEP and CHOEP groups according to their first-line chemotherapy regimens. The PSM method was used to match the baseline variables to balance the confounding factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>\nA cohort of 33 patients each in the C-CHOEP and CHOEP groups was generated after propensity score-matching (PSM). The complete remission (CR) rates of the C-CHOEP regimen were higher than that of the CHOEP regimen (56.3 <jats:italic>vs<\/jats:italic>. 25.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.014), whereas the duration of response of the C-CHOEP group was shorter (median DOR 30 <jats:italic>vs.<\/jats:italic> 57\u00a0months), resulting in roughly similar progression-free survival (PFS) and (overall survival) OS between the two groups. The responding patients who received chidamide maintenance therapy showed a trend of superior PFS and OS compared with patients who did not receive maintenance therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>\nThe C-CHOEP regimen was well tolerated but failed to show advantages over the CHOEP regimen in patients with untreated PTCL; however, the chidamide maintenance may contribute to a more durable response and stable long-term survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-023-03135-3","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:13:18Z","timestamp":1680714798000},"page":"2514-2522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study"],"prefix":"10.1007","volume":"25","author":[{"given":"Chong","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-8555","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"25","key":"3135_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/jco.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. https:\/\/doi.org\/10.1200\/jco.2008.16.4558.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3135_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/ajcp7yltqpusdq5c","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the world health organization classification. Am J Clin Pathol. 2012;138(3):429\u201334. https:\/\/doi.org\/10.1309\/ajcp7yltqpusdq5c.","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"3135_CR3","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1002\/cam4.3037","volume":"9","author":"W Liu","year":"2020","unstructured":"Liu W, Ji X, Song Y, Wang X, Zheng W, Lin N, et al. Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades. Cancer Med. 2020;9(11):3765\u201374. https:\/\/doi.org\/10.1002\/cam4.3037.","journal-title":"Cancer Med"},{"issue":"10","key":"3135_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single north American institution by the WHO classification. Ann Oncol. 2004;15(10):1467\u201375. https:\/\/doi.org\/10.1093\/annonc\/mdh392.","journal-title":"Ann Oncol"},{"issue":"3","key":"3135_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","volume":"129","author":"R Sonnen","year":"2005","unstructured":"Sonnen R, Schmidt WP, M\u00fcller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005;129(3):366\u201372. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05478.x.","journal-title":"Br J Haematol"},{"key":"3135_CR6","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-Cell lymphoma. ISRN Hematol. 2011. https:\/\/doi.org\/10.5402\/2011\/623924.","journal-title":"ISRN Hematol"},{"issue":"10","key":"3135_CR7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 2014;124(10):1570\u20137. https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"issue":"18","key":"3135_CR8","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-hodgkin lymphoma study group. Blood. 2010;116(18):3418\u201325. https:\/\/doi.org\/10.1182\/blood-2010-02-270785.","journal-title":"Blood"},{"issue":"5","key":"3135_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19(5):958\u201363. https:\/\/doi.org\/10.1093\/annonc\/mdn022.","journal-title":"Ann Oncol"},{"issue":"5","key":"3135_CR10","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/s2352-3026(18)30039-5","volume":"5","author":"M Gleeson","year":"2018","unstructured":"Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018;5(5):e190\u2013200. https:\/\/doi.org\/10.1016\/s2352-3026(18)30039-5.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3135_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-018-3488-1","volume":"98","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang W, Li J, Duan M, Han B, Zhu T, et al. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. Ann Hematol. 2019;98(1):143\u201350. https:\/\/doi.org\/10.1007\/s00277-018-3488-1.","journal-title":"Ann Hematol"},{"issue":"22","key":"3135_CR12","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334. https:\/\/doi.org\/10.1182\/blood-2010-10-312603.","journal-title":"Blood"},{"issue":"23","key":"3135_CR13","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients With relapsed or refractory Peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139. https:\/\/doi.org\/10.1200\/jco.2014.59.2782.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3135_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdv237.","journal-title":"Ann Oncol"},{"issue":"1","key":"3135_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3135_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","volume":"18","author":"W Zhang","year":"2021","unstructured":"Zhang W, Su L, Liu L, Gao Y, Wang Q, Su H, et al. The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm phase 1b\/2 study. Cancer Biol Med. 2021;18(3):841\u20138.","journal-title":"Cancer Biol Med"},{"key":"3135_CR17","volume-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008."},{"issue":"14","key":"3135_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejm199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394. https:\/\/doi.org\/10.1056\/nejm199309303291402.","journal-title":"N Engl J Med"},{"issue":"7","key":"3135_CR19","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139. https:\/\/doi.org\/10.1182\/blood-2003-09-3080.","journal-title":"Blood"},{"issue":"25","key":"3135_CR20","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/jco.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139. https:\/\/doi.org\/10.1200\/jco.2011.40.2719.","journal-title":"J Clin Oncol"},{"issue":"27","key":"3135_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/jco.2013.54.8800.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3135_CR22","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D Anderson Cancer Center Exp Cancer. 2005;103(10):2091\u20138. https:\/\/doi.org\/10.1002\/cncr.20999.","journal-title":"D Anderson Cancer Center Exp Cancer"},{"issue":"10168","key":"3135_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(18)32984-2.","journal-title":"Lancet"},{"issue":"3","key":"3135_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/jco.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the ro-CHOP Phase III study (Conducted by LYSA). J Clin Oncol. 2022;40(3):242\u201351. https:\/\/doi.org\/10.1200\/jco.21.01815.","journal-title":"J Clin Oncol"},{"key":"3135_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106705","author":"J Wang","year":"2021","unstructured":"Wang J, Fang Y, Ma S, Su N, Zhang Y, Huang H, et al. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma. Leuk Res. 2021. https:\/\/doi.org\/10.1016\/j.leukres.2021.106705.","journal-title":"Leuk Res"},{"key":"3135_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835103","author":"J Wang","year":"2022","unstructured":"Wang J, Su N, Fang Y, Ma S, Zhang Y, Cai J, et al. Comparison of chemotherapy combined with chidamide versus chemotherapy in the frontline treatment for peripheral T-cell lymphoma. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.835103.","journal-title":"Front Immunol"},{"issue":"16","key":"3135_CR27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370. https:\/\/doi.org\/10.1182\/blood.2020009004.","journal-title":"Blood"},{"issue":"1","key":"3135_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000500666","volume":"143","author":"F Lansigan","year":"2020","unstructured":"Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. Outcomes for relapsed and refractory peripheral T-Cell lymphoma patients after front-line therapy from the complete registry. Acta Haematol. 2020;143(1):40\u201350. https:\/\/doi.org\/10.1159\/000500666.","journal-title":"Acta Haematol"},{"key":"3135_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8175957","author":"C Irl\u00e9","year":"2016","unstructured":"Irl\u00e9 C, Weintraub J. Long-term treatment with romidepsin in patients with peripheral T-cell lymphoma. Case Rep Hematol. 2016. https:\/\/doi.org\/10.1155\/2016\/8175957.","journal-title":"Case Rep Hematol"},{"issue":"2","key":"3135_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000501070","volume":"12","author":"K Kitazume","year":"2019","unstructured":"Kitazume K, Akagawa Y, Wada S, Suzuki T, Fujita A. Pralatrexate for prolonged treatment of refractory peripheral T-cell lymphoma, not otherwise specified, with prophylactic leucovorin. Case Rep Oncol. 2019;12(2):529\u201336. https:\/\/doi.org\/10.1159\/000501070.","journal-title":"Case Rep Oncol"},{"issue":"9","key":"3135_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from Complete, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507\u201317. https:\/\/doi.org\/10.1002\/cncr.31861.","journal-title":"Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03135-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T19:29:07Z","timestamp":1687807747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03135-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["3135"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03135-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Study protocols were approved by the institutional review board of Peking Union Medical College Hospital. The requirement for informed consent was waived because of the use of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}